Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series Anews2026-08-11T12:00:44+00:00August 11th, 2026|Endpoints News|
Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatmentnews2026-08-11T11:00:15+00:00August 11th, 2026|Endpoints News|
Trump directs MMR vaccine to be split in three parts, backs autism claimnews2026-08-10T20:32:45+00:00August 10th, 2026|Endpoints News|
FDA rejects ITM’s radiopharma drug over manufacturing problemsnews2026-08-10T19:05:00+00:00August 10th, 2026|Endpoints News|
Bristol Myers details new $2.3B manufacturing campus in Houstonnews2026-08-10T18:20:19+00:00August 10th, 2026|Endpoints News|
Judge blocks enforcement of WuXi AppTec’s designation as Chinese military companynews2026-08-10T17:43:22+00:00August 10th, 2026|Endpoints News|
Scholar Rock drops Novo manufacturing site from SMA drug applicationnews2026-08-10T17:08:01+00:00August 10th, 2026|Endpoints News|
Sionna’s surprise cystic fibrosis trial failure sinks hopes of challenging Vertexnews2026-08-10T15:39:45+00:00August 10th, 2026|Endpoints News|
AbCellera details ‘striking’ Phase 2 data for vasomotor symptoms treatmentnews2026-08-10T15:33:49+00:00August 10th, 2026|Endpoints News|
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 winnews2026-08-10T15:33:02+00:00August 10th, 2026|Endpoints News|
